Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19164710 | 0.89 | PRMT6 (0.40) | RIPK1PRMT6 | |
| SCHEMBL14868587 | 0.82 | RIPK1 (0.48) | RIPK1PRMT6 | |
| SCHEMBL14868625 | 0.81 | PRMT6 (0.46) | RIPK1PRMT6 | |
| SCHEMBL19164711 | 0.74 | RIPK1 (0.34) | RIPK1PRMT6 | |
| SCHEMBL24433738 | 0.74 | PRMT6 (0.35) | RIPK1PRMT6 | |
| SCHEMBL14868736 | 0.74 | PRMT6 (0.46) | RIPK1PRMT6 | |
| SCHEMBL14868749 | 0.73 | PRMT6 (0.49) | PRMT6 | |
| SCHEMBL14868630 | 0.71 | RIPK1 (0.47) | RIPK1PRMT6 | |
| SCHEMBL14868627 | 0.71 | PRMT6 (0.53) | PRMT6 | |
| SCHEMBL14868644 | 0.70 | RIPK1 (0.37) | RIPK1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | RIPK1 3097/4885PRMT6 1349/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | RIPK1 3097/4885PRMT6 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.